Skip to main content
main-content

01.12.2017 | Research | Ausgabe 1/2017 Open Access

Tobacco Induced Diseases 1/2017

Economic evaluation of an exercise-counselling intervention to enhance smoking cessation outcomes: The Fit2Quit trial

Zeitschrift:
Tobacco Induced Diseases > Ausgabe 1/2017
Autoren:
William Leung, Vaughan Roberts, Louisa G. Gordon, Christopher Bullen, Hayden McRobbie, Harry Prapavessis, Yannan Jiang, Ralph Maddison

Abstract

Background

In the Fit2Quit randomised controlled trial, insufficiently-active adult cigarette smokers who contacted Quitline for support to quit smoking were randomised to usual Quitline support or to also receive ≤10 face-to-face and telephone exercise-support sessions delivered by trained exercise facilitators over the 24-week trial. This paper aims to determine the cost-effectiveness of an exercise-counselling intervention added to Quitline compared to Quitline alone in the Fit2Quit trial.

Methods

Within-trial and lifetime cost-effectiveness were assessed. A published Markov model was adapted, with smokers facing increased risks of lung cancer and cardiovascular disease.

Results

Over 24 weeks, the incremental programme cost per participant in the intervention was NZ$428 (US$289 or €226; purchasing power parity-adjusted [PPP]). The incremental cost-effectiveness ratio (ICER) for seven-day point prevalence measured at 24-week follow-up was NZ$31,733 (US$21,432 or €16,737 PPP-adjusted) per smoker abstaining. However, for the 52% who adhered to the intervention (≥7 contacts), the ICER for point prevalence was NZ$3,991 (US$2,695 or €2,105 PPP-adjusted). In this adherent subgroup, the Markov model estimated 0.057 and 0.068 discounted quality-adjusted life-year gains over the lifetime of 40-year-old males (ICER: NZ$4,431; US$2,993 or €2,337 PPP-adjusted) and females (ICER: NZ$2,909; US$1,965 or €1,534 PPP-adjusted).

Conclusions

The exercise-counselling intervention will only be cost-effective if adherence is a minimum of ≥7 intervention calls, which in turn leads to a sufficient number of quitters for health gains.

Trial registration

Australasian Clinical Trials Registry Number ACTRN12609000637​246
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Tobacco Induced Diseases 1/2017 Zur Ausgabe